Abstracts tagged "etanercept"

Abstract Number: 2002 • 2012 ACR/ARHP Annual Meeting
Randomized Clinical Trial in Pediatric Rheumatology: Are Parents and Patients in Equipoise?
Petra C.E. Hissink Muller¹, Bahar Yildiz¹, Cornelia F. Allaart², Danielle M.C. Brinkman³, Marion A. J. Van Rossum⁴, J. Merlijn Van den Berg⁵, Lisette W.A. Van Suijlekom-Smit⁶, Rebecca Ten Cate¹ and Martine C. de Vries⁷, ¹Pediatric Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Pediatric Rheumatology, Rijnland Hospital, Leiderdorp, Netherlands, ⁴Department of Pediatric Rheumatology and Immunology, Emma Children's Hospital / Academic Medical Center and Reade Institute, Amsterdam, Netherlands, ⁵Pediatric Rheumatology, Emma Children's Hospital / Academic Medical Centre and Reade Institute, Amsterdam, Netherlands, ⁶Pediatric Rheumatology, Erasmus MC Sophia Children's Hospital, Rotterdam, Netherlands, ⁷Medical Ethics and Health Law, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: It is an ethical requirement for setting up a randomized controlled trial (RCT) that the physician-investigator must have genuine uncertainty about the therapeutic options.…
Abstract Number: 386 • 2012 ACR/ARHP Annual Meeting
Costs of Tumor Necrosis Factor Blockers Per Treated Rheumatoid Arthritis Patient Using Real-World Drug Data in a US Managed Care Population
Vernon F. Schabert¹, Crystal Watson², George Joseph², Paige Iversen¹, Chakkarin Burudpakdee¹ and David J. Harrison², ¹IMS Health, Alexandria, VA, ²Amgen Inc., Thousand Oaks, CA
Background/Purpose: Etanercept (ETN), adalimumab (ADA), and infliximab (INF) are FDA-approved tumor necrosis factor (TNF)-blocker treatments for moderate to severe rheumatoid arthritis (RA) and are commonly…
Abstract Number: 1829 • 2012 ACR/ARHP Annual Meeting
Cost of Etanercept, Adalimumab, and Infliximab in Patients with Rheumatoid Arthritis with Employer Provided Health Insurance
Machaon Bonafede¹, Crystal Watson², George Joseph², Nicole Princic¹ and David J. Harrison², ¹Thomson Reuters Healthcare, Cambridge, MA, ²Amgen Inc., Thousand Oaks, CA
Background/Purpose: Tumor Necrosis Factor Inhibitors (TNFi) are the mainstay of treatment for rheumatoid arthritis (RA) in patients with moderate to severe disease. The three most…
Abstract Number: 368 • 2012 ACR/ARHP Annual Meeting
Impact of Etanercept-Methotrexate Therapy On Patient-Reported Outcomes in Rheumatoid Arthritis Patients with up to 12 Months of Symptoms
Paul Emery¹, Piotr Wiland², Wolfgang Spieler³, Jean Dudler⁴, Stefanie Gaylord⁵, Theresa Williams⁵, Ronald Pedersen⁵, Andrew S. Koenig⁵, Bonnie Vlahos⁵ and Sameer Kotak⁶, ¹Department of Rheumatology, Leeds General Infirmary, Leeds, United Kingdom, ²Department of Rheumatology and Internal Medicine, Wroclaw Medical University, Wroclaw, Poland, ³Osteologie und Rheumatologie, ZeFOR GmbH Zentrum für Forschung, Zerbst, Germany, ⁴Department of Rheumatology, University Hospital of Lausanne, Lausanne, Switzerland, ⁵Department of Specialty Care, Pfizer Inc., Collegeville, PA, ⁶Department of Specialty Care, Pfizer Inc., New York, NY
Background/Purpose: Patient-reported outcomes (PROs) in patients with rheumatoid arthritis (RA) are critical in evaluating RA treatment effects on function and health-related quality of life (HR-QoL).…
Abstract Number: 1641 • 2012 ACR/ARHP Annual Meeting
When Can Biological Therapy Be Resumed in Patients with Rheumatic Conditions Who Develop Tuberculosis Infection During Tumour Necrosis Factors Antagonists Therapy? Study Based On the Biobadaser Data Registry
Maria Victoria Hernández¹, Miguel A. Descalzo², Juan D. Cañete¹, Raimon Sanmarti³ and BIOBADASER Study Group⁴, ¹Rheumatology, Hospital Clínic of Barcelona. IDIBAPS. University of Barcelona, Barcelona, Spain, ²Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ³Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ⁴Research Unit. Spanish Society of Rheumatology, Madrid, Spain
Background/Purpose: Tuberculosis infection (TI) is one of the most serious adverse events related to tumour necrosis factor (TNF) antagonists. According to the current treatment guidelines…
Abstract Number: 275 • 2012 ACR/ARHP Annual Meeting
Pediatric Rheumatology Practitioners Experience with Biologics in Juvenile Dermatomyositis: Survey Results
Anjali Patwardhan¹, Kelly A. Rouster-Stevens², Harry L. Gewanter³, Grant D. Syverson⁴, Renee F. Modica⁵, Kara M. Schmidt⁶ and Charles H. Spencer⁷, ¹Pediatric Rheumatology, Nationwide Childrens Hospital, Columbus, OH, ²Pediatric Rheumatologist, Emory-Children's Center, Atlanta,, GA, ³Pediatric & Adolescent HP, Pediatric & Adolescent HP, Midlothian, VA, ⁴Pediatric Rheumatology, Medical College of Wisconsin, Wauwatosa, WI, ⁵Pediatric Rheumatology, University of Florida, Gainesville, FL, ⁶Pediatric Rheumatology, Univ of Louisville, Louisville, KY, ⁷Rheumatology, Nationwide Childrens Hospital, Columbus, OH
Background/Purpose: Biologic therapy is increasingly prescribed in rheumatologic disorders. Juvenile dermatomyositis (JDM), the most common inflammatory myopathy in children, can be challenging to manage in…
Abstract Number: 1644 • 2012 ACR/ARHP Annual Meeting
Enhanced Pharmacovigilance Reporting of Malignancies in Children and Young Adults Taking Etanercept
Michele Hooper¹, Deborah Wenkert², Bojena Bitman³, Virgil C. Dias⁴, Yessinia Bartley⁵, Julie Wang⁶ and Julia R. Gage⁷, ¹Amgen Global Safety, Amgen Inc., Thousand Oaks, CA, ²Inflammation TA, Amgen Inc., Thousand Oaks, CA, ³Amgen, Inc., San Francisco, CA, ⁴Amgen Inc., Thousand Oaks, CA, ⁵Assent Consulting, Solana Beach, CA, ⁶Amgen Inc, One Amgen Center Drive, Thousand Oaks, CA, ⁷Gage Medical Writing, LLC, Oak Park, CA
Background/Purpose: Recent reports suggest an increased rate of malignancy in children with juvenile idiopathic arthritis (JIA) (Simard, A&R 2010;62:3776; Beukelman A&R 2012;64:1263). In 2011, the…
Abstract Number: 5 • 2012 ACR/ARHP Annual Meeting
Adalimumab Inhibits TNF-Enhanced Human Osteoclast Development More Effectively Than Other Biologic Agents Under in Vitro Conditions of Chronic TNF Exposure
Bohdan P. Harvey¹ and Zehra Kaymakcalan², ¹Biologics, Abbott Laboratories, Worcester, MA, ²Biologics, Abbott, Worcester, MA
Background/Purpose: TNF-alpha (TNFa) has been shown to contribute to osteoclastogenesis independently and in conjunction with M-CSF or RANKL, two key cytokines involved in osteoclast development. …
Abstract Number: 1317 • 2012 ACR/ARHP Annual Meeting
One-Year Results From the Canadian Methotrexate and Etanercept Outcome Study: A Randomized Trial of Etanercept and Methotrexate Versus Etanercept Alone in Rheumatoid Arthritis
Janet E. Pope¹, Boulos Haraoui², J. Carter Thorne³, Melanie Poulin-Costello⁴, Andrew Vieira⁵ and Edward Keystone⁶, ¹Medicine/Rheumatology, St. Joseph Health Care London, University of Western Ontario, London, ON, Canada, ²Institut de Rhumatologie de Montréal, Montreal, QC, Canada, ³Southlake Regional Health Centre, Newmarket, ON, Canada, ⁴Biostatistics, Amgen Canada Inc., Mississauga, ON, Canada, ⁵Amgen Canada Inc., Mississauga, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada
Background/Purpose: Combination therapy with a biologic and methotrexate (MTX) usually yields better outcomes than biologic monotherapy in rheumatoid arthritis (RA).1,2,3 However, patients may be intolerant…
Abstract Number: 1334 • 2012 ACR/ARHP Annual Meeting
Intra-Articular Etanercept Treatment in Inflammatory Arthritis: A Randomized Double-Blind Placebo-Controlled Trial
Caroline J. Aalbers¹, Danielle M. Gerlag², Koen Vos¹, Gertjan Wolbink³, R. Landewe¹ and Paul P. Tak⁴, ¹Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ²Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁴Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam and GlaxoSmithKline, Amsterdam, Netherlands
Background/Purpose: The use of intra-articular (IA) corticosteroid injections has been widely accepted as a therapy to control local inflammation. Studies on the use of IA…
Abstract Number: 1314 • 2012 ACR/ARHP Annual Meeting
Validation of Algorithms Using Genome-Wide SNP Analysis for Prediction of Remission or Low Disease Activity for Infliximab or Etanercept-Treated RA Patients
Tsukasa Matsubara¹, Satoru Koyano², Keiko Funahashi², James E. Middleton², Takako Miura¹, Kosuke Okuda¹, Takeshi Nakamura¹, Akira Sagawa³, Takeo Sakurai⁴, Hiroaki Matsuno⁵, Tomomaro Izumihara⁶, Eisuke Shono⁷, Kou Katayama⁸, Toyomitsu Tsuchida⁹, Mitsuyoshi Iwahashi¹⁰, Tomomi Tsuru¹¹ and Motohiro Oribe¹², ¹Matsubara Mayflower Hospital, Kato, Japan, ²Research Institute of Joint Diseases, Kobe, Japan, ³Sagawa Akira Rheumatology Clinic, Sapporo, Japan, ⁴Inoue Hospital, Takasaki, Japan, ⁵Matsuno Clinic for Rheumatic Diseases, Toyama, Japan, ⁶Izumihara Rheumatic and Medical Clinic, Kagoshima, Japan, ⁷Shono Rheumatology Clinic, Fukuoka, Japan, ⁸Katayama Orthopedic Rheumatology Clinic, Asahikawa, Japan, ⁹Tsuchida Clinic, Chiba, Japan, ¹⁰Higashi-Hiroshima Memorial Hospital, Higashi-hiroshima, Japan, ¹¹PS Clinic, Fukuoka, Japan, ¹²Oribe Rheumatism and Internal Medicine Clinic, Oita, Japan
Background/Purpose: Achievement of remission or low disease activity with infliximab (IFX) and etanercept (ETN) treatment is currently one of the most important matters in RA…
Abstract Number: 1285 • 2012 ACR/ARHP Annual Meeting
Short-Term Efficacy of Etanercept Plus Methotrexate Vs.Various Disease-Modifying Anti-Rheumatic Combinations with Methotrexate in Established Rheumatoid Arthritis
Roy Fleischmann¹, Andrew S. Koenig², Annette Szumski³, Henk Nab⁴, Lisa Marshall⁵ and Eustratios Bananis³, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²Specialty Care Business Unit, Pfizer Inc., Collegeville, PA, ³Specialty Care, Pfizer Inc., Collegeville, PA, ⁴Pfizer Europe, Rome, Italy, ⁵Pfizer Inc., Collegeville, PA
Background/Purpose: The objective of this study was to assess the short-term benefit of etanercept (ETN) + methotrexate (MTX) vs. various disease-modifying anti-rheumatic drugs (DMARDs; hydroxychloroquine…
Abstract Number: 1286 • 2012 ACR/ARHP Annual Meeting
Antibodies to Etanercept and Adalimumab in Rheumatoid Arthritis Inadequate Responders and Clinical Outcomes After an Active Switch to Infliximab
Chad Pool¹, Gopi Shankar², Allen Schantz², George Gunn², Rebecca Bolce³, Marjatta Leirisalo-Repo⁴, Jim Wang¹, John A. Goldman⁵, Raphael J. DeHoratius⁶, Roy Fleischmann⁷ and Dennis Decktor⁶, ¹Janssen Services, LLC, Horsham, PA, ²Janssen R&D, LLC, PA, ³Crescendo Bioscience Inc., South San Francisco, CA, ⁴Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital, Helsinki, Finland, ⁵Medical Quarters #293, Atlanta, GA, ⁶Medical Affairs, Janssen Services, LLC, Horsham, PA, ⁷Rheumatology, University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: To determine if RA patients (pts) who had an inadequate response to etanercept(ETN) or adalimumab(ADA) and developed antibodies (Abs) to ETN or ADA responded…
Abstract Number: 1275 • 2012 ACR/ARHP Annual Meeting
Fast Remission Response to Etanercept At Week 4 Predicts Better Long-Term Outcomes in Early and Established Rheumatoid Arthritis Compared to Slower Response At Week 12
Bernd Raffeiner¹, Costantino Botsios², Francesca Ometto², Mariagrazia Canova², Livio Bernardi², Cristiana Vezzari², Silvano Todesco², Paolo Sfriso² and Leonardo Punzi², ¹Rheumatology Unit, Department of Medicine - DIMED, University of Padova, Padova, Italy, ²Clinical and Experimental Medicine, Rheumatology Unit - University of Padova, Padova, Italy
Background/Purpose: Achievement of clinical remission not only early in disease course but also early in treatment course may be critical for functional outcome of patients…
Abstract Number: 1165 • 2012 ACR/ARHP Annual Meeting
Factors Associated with Achievement of Inactive Disease in Children with Juvenile Idiopathic Arthritis Treated with Etanercept
Nicoletta Solari¹, Elena Palmisani¹, Alessandro Consolaro¹, Sara Dalprà¹, Benedetta Schiappapietra¹, Giulia Bracciolini¹, Silvia Rosina¹, Giorgia Negro¹, Alberto Martini² and Angelo Ravelli³, ¹Pediatria II, Istituto Giannina Gaslini, Genova, Italy, ²Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH, ³Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: The advent of new therapies for juvenile idiopathic arthritis (JIA), particularly the introduction of biologic medications, has increased considerably the potential for treatment benefit,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].